HER2 testing in gastric cancer: An update

作者：Lucas Faria Abrahão‐Machado, Cristovam Scapulatempo‐Neto · 发表于：World Journal of Gastroenterology · 年份：2016 · DOI：10.3748/wjg.v22.i19.4619 · 被引用次数：319 · 研究领域：HER2/EGFR in Cancer Research、Monoclonal and Polyclonal Antibodies Research、Glycosylation and Glycoproteins Research

Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.